Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use NUCYNTA® ER safely and effectively. See full prescribing information for NUCYNTA® ER NUCYNTA® ER (tapentadol) extended-release tablets for oral use C-II Initial U.S. Approval: 2008
Medication labelWhy this: Advisory · dailymed-prescription
NUCYNTA ER (tapentadol) is indicated for the management of: Severe and persistent pain in adults that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. Severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1)], reserve opioid analgesics, including NUCYNTA ER, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. NUCYNTA ER is not indicated as an as-needed (prn) analgesic.
- generic_name
- tapentadol hydrochloride
- product_names
- tapentadol hydrochloride
- ndc
- 24510-058, 24510-116, 24510-174, 24510-232, 24510-291, 24510-058-60, 24510-058-01, 24510-116-60, 24510-116-01, 24510-174-60, 24510-174-01, 24510-232-60, 24510-232-01, 24510-291-60, 24510-291-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en